(Hypertension. 2002;39:251.)
© 2002 American Heart Association, Inc.
Scientific Contributions |
From the Cardiovascular Disease Research Program, Julius L. Chambers Biomedical Biotechnology Research Institute, North Carolina Central University (R.D.B., Y.W.), Durham; National Institute on Alcohol Abuse & Alcoholism, National Institutes of Health (S.B., Z.J., L.O., G.K.), Bethesda, Md; and Department of Biological Sciences, Western Michigan University (W.F.J.), Kalamazoo.
Correspondence to Richard Bukoski, PhD, Director, Cardiovascular Disease Research Program, Julius L. Chambers Biomedical Biotechnology Research Institute, North Carolina Central University, 700 George St, Durham, NC 27707. E-mail rbukoski{at}wpo.nccu.edu
| Abstract |
|---|
|
|
|---|
-glycyrrhetinic acid, a gap junction blocker, were without effect. SR141716A (1 to 30 µmol/L) was also assessed for nonspecific actions on whole-cell K+ currents in isolated vascular smooth muscle cells. SR141716A inhibited macroscopic K+ currents at concentrations higher than those required to inhibit Ca2+-induced relaxation, and appeared to have little effect on currents through large conductance Ca2+-activated K+ channels. These data indicate that arteries of the mouse relax in response to cumulative addition of extracellular Ca2+ in a hyperpolarization-dependent manner and rule out a role for CB1 or CB2 receptors in this effect. The possible role of a nonclassical cannabinoid receptor is discussed.
Key Words: mesenteric arteries calcium relaxation potassium channels
| Introduction |
|---|
|
|
|---|
Over the past 2 years, several reports have appeared that indicate that in addition to its high potency as a CB1 receptor antagonist,8 at concentrations of
10 µmol/L, SR141716A also has activity as an antagonist of type 2 cannabinoid (CB2) receptors,8 Ca2+ entry channels,9 KCa channels,9 and gap junctions.10 Although we have found that lower concentrations of SR141716A inhibit the mesenteric vasodilator response to anandamide,4 we believed it was important to obtain additional information regarding whether Ca2+-induced relaxation is mediated by the CB1 receptor. The CB1-/- mouse11 offers a direct means of testing the hypothesis that Ca2+-induced relaxation is mediated by a transmitter with activity at the CB1 receptor. We have therefore performed experiments to (1) determine whether arteries isolated from mice undergo extracellular Ca2+-induced relaxation and whether the relaxation shares properties with the relaxation observed in rats and (2) to test the hypothesis that Ca2+-induced relaxation is mediated by the CB1 receptor.
| Methods |
|---|
|
|
|---|
Immunocytochemistry
Mesenteric branch arteries were microdissected from isolated mesenteries and prepared for immunostaining as described previously.2 Fixed and blocked segments were incubated overnight with a polyclonal anti-Ca2+ receptor antibody (1:50, Affinity Bioreagents) in the presence or absence of excess antigen. Anti-rabbit IgG conjugated with Texas Red (1:300, Molecular Probes) was used as the secondary antibody. Vessel segments were viewed using a Zeiss LSM 510 confocal microscope and 63x water immersion objective (Zeiss Instruments).
Biophysical Measurements
Isometric force generation was measured using previously described methods.2 Relaxation to Ca2+ or acetylcholine was assessed by cumulatively adding the agent to vessels that had been precontracted to a steady-state tension using 5 µmol/L norepinephrine (NE). The percentage of relaxation was calculated taking the magnitude of the prerelaxation tone as 100% of the amount that the vessel could relax. When the effect of an antagonist, ie, SR141716A, was assessed on the relaxation response, the vessel was pretreated with the compound for 10 to 15 minutes. Afterward, the contraction was induced by the addition of NE, and the response to the dilator assessed.
An expanded Biophysical Measurements section can be found in an online data supplement available at http://www.hypertensionaha.org.
Electrophysiology
Vascular smooth muscle cells were enzymatically isolated from hamster cremasteric arterioles using a papain digestion medium as described previously.12 Macroscopic K+ currents were measured using the conventional whole cell recording method.13 Currents were measured, and membrane potential was clamped with a Warner PC-505A patch-clamp amplifier (Warner Instrument Corp), filtered at 1 kHz, and sampled at 5 kHz. As reported previously, all currents were normalized to cell capacitance to account for any differences in cell size. Cells were held at -60 mV and then stepped, for 400 ms, to test potentials from -90 to 60 mV in 10-mV increments. The average current during the last 200 ms of the test pulse was then measured at each potential and used to construct current/voltage relationships.
An expanded Electrophysiology section can be found in an online data supplement available at http://www.hypertensionaha.org.
Materials
SR141716A and SR144538 were obtained from Sanofi Recherche and dissolved in absolute ethanol; O-1918 was synthesized by Dr Raj Razdan (Organix Inc, Woburn, Mass) and dissolved in ethanol. All other chemicals were of reagent grade or better and obtained from Sigma Chemical or other commercial suppliers, as dictated by the purchasing regulations of the University of North Carolina System.
Statistical Analysis
The agonist concentration eliciting 50% of the maximal relaxation (EC50) was determined from plots of the percentage of initial tension versus the concentration of agonist. All data are presented as mean±SEM, and statistical analysis was performed using the SYSTAT software package. Comparisons among groups were performed using ANOVA with a repeated measures design when appropriate. A value of P<0.05 was taken to indicate a statistically significant difference.
| Results |
|---|
|
|
|---|
|
Mesenteric branch arteries isolated from C57 control mice and precontracted with 5 µmol/L NE relaxed in response to cumulative addition of extracellular Ca2+, with a maximal relaxation response of 72.0±6.3% of the prerelaxation tone (n=6) and an EC50 for Ca2+ of 2.9±0.54 mmol/L (Figure 2A). To learn whether Ca2+-induced relaxation of mouse arteries is dependent on functional K+ channels, the relaxation response was also determined in vessels precontracted with 100 mmol/L K+ or pretreated with 10 mmol/L tetraethylammonium (TEA). Precontraction with a depolarizing concentration of K+ converted the Ca2+-induced relaxation into a Ca2+-induced contraction (Figure 2A). Moreover, pretreatment with 10 mmol/L TEA significantly inhibited the relaxation induced by cumulative addition of extracellular Ca2+ (Figure 2B). Because a residual relaxation to Ca2+ was observed in the presence of 10 mmol/L TEA, we tested the hypothesis that this component is mediated by NO. Pretreatment with 0.3 mmol/L NG-nitro-L-arginine methyl ester, however, was without further inhibitory effect (Figure 2B).
|
Branch arteries isolated from CB1-/- animals and CB1+/+ littermates were also studied. Ca2+ caused a concentration- dependent relaxation of CB1-/- arteries that was not different from that observed in vessels isolated from CB1+/+control animals (maximal relaxation response, 75.5±6.9%, P=0.954; EC50, 3.2±0.28 mmol/L, n=6, P=0.714) (Figure 3A). The response of CB1+/+ and CB1-/-arteries to the cumulative addition of acetylcholine was also assessed. Acetylcholine induced concentration-dependent relaxation of arteries isolated from both the wild-type and knockout strains (data not shown). No differences in either the maximal response or the sensitivity of the arteries to acetylcholine were detected (maximal CB1+/+ response versus CB1-/-, 76.9±7.5% versus 78.3±10.7%, n=3 and n=4, respectively, P=0.998; EC50 CB1+/+ versus CB1-/-, 0.71±0.42 versus 0.21±0.15 µmol/L, P=0.888).
|
Preincubation of vessels with increasing concentrations of the CB1 antagonist SR141716A dose-dependently inhibited Ca2+-induced relaxation of NE-precontracted arteries isolated from both the CB1-/- strain (Figure 3B) and the CB1+/+ control (Figure 3C). These data indicate that the threshold for SR141617A inhibition of Ca2+-induced relaxation is <300 nmol/L and that the IC50 lies between 300 nmol/L and 1 µmol/L.
To learn whether the blockade by SR141716A might be mediated by antagonist activity at the CB2 receptor, we assessed the effect of pretreatment with the selective CB2 antagonist SR144538.14 Pretreatment with 1 µmol/L SR144538 had no effect on relaxation induced by Ca2+ in arteries isolated from either the knockout or wild-type animals (Figure 4A). To assess the possible role of gap junctional activity in the relaxation response, the effect of preincubation with 18
-glycyrrhetinic acid (50 µmol/L), a gap junction blocker10 was assessed. 18
-glycyrrhetinic acid had no effect on the relaxation response determined in vessels from 4 animals (Figure 4B). Our previous data indicate that Ca2+-induced relaxation is inhibited by iberiotoxin, a selective inhibitor of large conduct KCa channels.4 To learn whether a possible nonselective effect of SR141716A at K+ channels plays a role in the inhibition of Ca2+-induced relaxation, we assessed the effect of a range of concentrations of SR141716A on whole-cell K+ channel currents in isolated vascular smooth muscle cells. SR141716A inhibited macroscopic K+ currents in a concentration-dependent fashion, (Figure 5A), with maximal effects observed at 10 µmol/L (Figure 5B). To learn whether SR141716A blocks KCa channel activity, we tested whether the inhibitory action of the antagonist was additive with respect to TEA. Initial experiments showed that TEA (1 mmol/L) and iberiotoxin (100 nmol/L) inhibit whole-cell K+ channel currents to a similar degree and in a nonadditive fashion (Figure 6A). In contrast, the K+-blocking effect of SR141716A was clearly additive to the inhibition produced by 1 mmol/L TEA (Figure 6B and 6C) or 100 nmol/L iberiotoxin (n=3, data not shown). These observations suggest that SR141716A has little effect on currents through large conductance KCa channels.
|
|
|
A previous report15 from one of our laboratories (G.K.) showed that abnormal-cannabidiol induces relaxation of the isolated perfused mesenteric artery bed of the rat and mouse and that the relaxation is blocked by cannabidiol and by SR141716A. We therefore assessed the effect of a novel cannabidiol analog, O-1918, that has been found to block abnormal cannabidiol-induced relaxation in isolated rat arteries (S. Batkai and G. Kunos, 2001, unpublished observations). Pretreatment of arteries isolated from C57BL/6 wild-type mice and CB1-/- mice with 10 µmol/L O-1918 for 15 minutes caused significant inhibition of Ca2+-induced relaxation (Figure 7A and 7B), whereas it was without effect on relaxation induced by acetylcholine (Figure 7C).
|
| Discussion |
|---|
|
|
|---|
Earlier studies, performed using arteries isolated from the rat, showed that when care is taken to preserve the integrity of the vascular adventitia, cumulative addition of extracellular Ca2+ causes concentration-dependent relaxation.2 In recent studies of arterial segments mounted on 14-µm gold wires, we have found EC50 values for Ca2+ of 1.45±0.02 mmol/L (R.D. Bukoski, 2001, unpublished observations), which is well within the range of the concentrations that have been shown to occur in the interstitial fluid compartment of the small bowel16 and renal cortex.17 The relaxation is attenuated by sensory denervation and correlates with the presence of Ca2+ receptor-positive nerve fibers.2 Ca2+-induced relaxation of rat arteries has also been shown to be inhibited by blockers of the large conductance KCa channel4,5 and by SR141716A4, a compound with CB1 antagonist activity.8 Moreover, the relaxation is mimicked by anandamide, an endocannabinoid CB1 receptor agonist18 with hyperpolarizing vasodilator activity.1921 Together, these observations have led to the hypothesis that changes in the concentration of Ca2+ in the interstitial fluid compartment are sensed by a sensory nerve Ca2+ receptor, and activation of this receptor is coupled with the release of an endocannabinoid-like hyperpolarizing vasodilator transmitter with activity at the CB1 receptor.1
The present studies demonstrate that perivascular nerves of mouse mesenteric branch arteries express Ca2+ receptor protein. These findings extend our prior demonstration that dorsal root ganglia of the rat express cDNA encoding a protein that is homologous with rat kidney Ca2+ receptor2; that DRG and mesenteric arteries express a protein that is immunoreactive with the parathyroid Ca2+ receptor2; and that arteries isolated from the mesentery, kidney, and brain of the rat express Ca2+ receptor-positive protein.22 As in the rat, Ca2+-induced relaxation of the mouse mesenteric artery is completely blocked by precontraction of the vessel segment with a depolarizing concentration of potassium chloride and is significantly attenuated by blockade of K+ channel activity with 10 mmol/L TEA.2 These observations suggest the involvement of K+ channels and a hyperpolarization-dependent mechanism of relaxation. To our knowledge, this is the first demonstration of Ca2+ receptor expression in perivascular nerves and high sensitivity Ca2+-induced relaxation of a species other than the rat.
The second new finding of the present study is the observation that Ca2+-induced relaxation occurs in mesenteric branch artery segments isolated from CB1 receptor knockout mice. These experiments were designed to follow up on the prior observation that Ca2+-induced relaxation in the rat is blocked by SR141716A and to directly test the hypothesis that Ca2+-induced relaxation requires an active CB1 receptor. The results clearly indicate that the CB1 receptor is not involved in the Ca2+-induced relaxation event in the mouse.
A third finding that merits discussion is our observation that Ca2+-induced relaxation of mouse artery is inhibited by SR141716A. This supports our earlier finding obtained using the rat.4 In addition, the observation that the sensitivity of Ca2+-induced relaxation to inhibition by SR141716A is similar in arteries isolated from the CB1-/- knockout and wild-type control argues against the possibility that SR141716A inhibits Ca2+-induced relaxation via CB1 receptors in wild-type mice, but suggests that a different site is involved in the inhibition observed in CB1 receptor knockout mice.
As noted in the Introduction, one possible explanation for our finding that Ca2+-induced relaxation is intact in the CB1 knockout mouse, yet is blocked by SR141716A, is that the blockade by SR141716A is mediated by nonspecific actions of the compound. As noted above, it has been reported that at high micromolar concentrations, SR141716A blocks CB2 receptors,8 gap junctions,10 Ca2+ entry channels,10 and KCa channels.10 Our finding that SR144538, a selective CB2 antagonist, had no effect on Ca2+-induced relaxation in the CB1 knockout animal indicates that SR141716A is not blocking the relaxation through a CB2 receptor effect. Moreover, our finding that 18
-glycyrrhetinic acid, a compound with gap junction-blocking activity,10 has no effect on Ca2+ relaxation in the rat makes it unlikely that SR141716A is attenuating Ca2+-induced relaxation through a gap junction-blocking effect. It also seems unlikely that SR141716A is blocking Ca2+-induced relaxation by inhibiting L-type Ca2+ channels because L-type Ca2+ channel inhibition is generally associated with a decrease in agonist-induced contraction and not blockade of a relaxation event.
In view of the fact that Ca2+-induced relaxation is antagonized by the selective large conductance KCa channel antagonist iberiotoxin,4 we were particularly concerned about the contribution of possible K+ channel-blocking activity of SR1416171A, as has been reported by White and Hiley.9 To directly address this issue, we determined the effect of a range of concentrations of SR141716A on whole-cell K+ channel currents in isolated vascular smooth muscle cells. The results showed clearly that SR141716A causes concentration-dependent inhibition of these currents. Two findings are of particular interest for the present study. One is that 1 µmol/L SR141716A caused <8% inhibition of K+ channel current, whereas the same concentration inhibited Ca2+-induced relaxation by >60%. A second finding is that the effect of SR141716A is additive to the effect of TEA and iberiotoxin. This suggests that SR141716A inhibits K+ channels other than KCa channels, presumably voltage-dependent K+ channels, which are less sensitive to SR141716A than the site at which SR141716A inhibits Ca2+-induced relaxation. In view of these observations, it seems unlikely that the inhibitory effect of SR141716A on Ca2+-induced relaxation is mediated by an inhibition of either KCa or voltage-dependent K+ channel activity.
A second possible explanation for our finding that Ca2+-induced relaxation is intact in the CB1 knockout mouse, yet is blocked by SR141716, is that SR141716A is blocking a nonclassical cannabinoid receptor. Kunos and colleagues15 have recently demonstrated that abnormal cannabidiol, an analog of the nonpsychoactive marijuana-constituent cannabidiol,23 causes relaxation of the isolated rat mesenteric bed. They further found that both anandamide and abnormal cannabidiol have mesenteric vasodilator activity in the CB1 knockout mouse, and the effect of both compounds is antagonized by SR141716A or cannabidiol.15 These findings have been interpreted to indicate that anandamide and other endocannabinoids can modulate vascular function by activating a nonclassical cannabinoid receptor. Of interest, in the present report, we show that O-1918, a novel analog of cannabidiol that blocks abnormal cannabidiol-induced relaxation in isolated rat and mouse mesenteric arteries (S. Batkai and G. Kunos, 2001, unpublished observations), blocks Ca2+-induced but not acetylcholine relaxation in isolated mouse arteries. This observation provides further support for the hypothesis that Ca2+-induced relaxation is mediated by sensory nerve dependent release of an endocannabinoid, possibly anandamide, which diffuses to underlying vascular smooth muscle and activates a specific anandamide receptor, which induces hyperpolarizing relaxation.
| Acknowledgments |
|---|
Received June 15, 2001; first decision July 17, 2001; accepted October 11, 2001.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
M. Waldeck-Weiermair, C. Zoratti, K. Osibow, N. Balenga, E. Goessnitzer, M. Waldhoer, R. Malli, and W. F. Graier Integrin clustering enables anandamide-induced Ca2+ signaling in endothelial cells via GPR55 by protection against CB1-receptor-triggered repression J. Cell Sci., May 15, 2008; 121(10): 1704 - 1717. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Awumey, S. K. Hill, D. I. Diz, and R. D. Bukoski Cytochrome P-450 metabolites of 2-arachidonoylglycerol play a role in Ca2+-induced relaxation of rat mesenteric arteries Am J Physiol Heart Circ Physiol, May 1, 2008; 294(5): H2363 - H2370. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Awumey, A. C. Howlett, J. W. Putney Jr., D. I. Diz, and R. D. Bukoski Ca2+ mobilization through dorsal root ganglion Ca2+-sensing receptor stably expressed in HEK293 cells Am J Physiol Cell Physiol, May 1, 2007; 292(5): C1895 - C1905. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Awumey, A. C. Howlett, and D. I. Diz Is there a role for anandamide in cardiovascular regulation? Insights from studies of endocannabinoid metabolism Am J Physiol Heart Circ Physiol, August 1, 2005; 289(2): H520 - H521. [Full Text] [PDF] |
||||
![]() |
A. Kofalvi, R. J. Rodrigues, C. Ledent, K. Mackie, E. S. Vizi, R. A. Cunha, and B. Sperlagh Involvement of Cannabinoid Receptors in the Regulation of Neurotransmitter Release in the Rodent Striatum: A Combined Immunochemical and Pharmacological Analysis J. Neurosci., March 16, 2005; 25(11): 2874 - 2884. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Batkai, P. Pacher, D. Osei-Hyiaman, S. Radaeva, J. Liu, J. Harvey-White, L. Offertaler, K. Mackie, M. A. Rudd, R. D. Bukoski, et al. Endocannabinoids Acting at Cannabinoid-1 Receptors Regulate Cardiovascular Function in Hypertension Circulation, October 5, 2004; 110(14): 1996 - 2002. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Koura, A. Ichihara, Y. Tada, Y. Kaneshiro, H. Okada, C. J. Temm, M. Hayashi, and T. Saruta Anandamide Decreases Glomerular Filtration Rate through Predominant Vasodilation of Efferent Arterioles in Rat Kidneys J. Am. Soc. Nephrol., June 1, 2004; 15(6): 1488 - 1494. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Begg, F.-M. Mo, L. Offertaler, S. Batkai, P. Pacher, R. K. Razdan, D. M. Lovinger, and G. Kunos G Protein-coupled Endothelial Receptor for Atypical Cannabinoid Ligands Modulates a Ca2+-dependent K+ Current J. Biol. Chem., November 14, 2003; 278(46): 46188 - 46194. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Wang, E. K. Awumey, P. K. Chatterjee, C. Somasundaram, K. Bian, K. V. Rogers, C. Dunn, and R. D. Bukoski Molecular cloning and characterization of a rat sensory nerve Ca2+-sensing receptor Am J Physiol Cell Physiol, July 1, 2003; 285(1): C64 - C75. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. B. Clement, E. G. Hawkins, A. H. Lichtman, and B. F. Cravatt Increased Seizure Susceptibility and Proconvulsant Activity of Anandamide in Mice Lacking Fatty Acid Amide Hydrolase J. Neurosci., May 1, 2003; 23(9): 3916 - 3923. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Offertaler, F.-M. Mo, S. Batkai, J. Liu, M. Begg, R. K. Razdan, B. R. Martin, R. D. Bukoski, and G. Kunos Selective Ligands and Cellular Effectors of a G Protein-Coupled Endothelial Cannabinoid Receptor Mol. Pharmacol., March 1, 2003; 63(3): 699 - 705. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2002 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |